Table of Contents
J. Clin. Med., Volume 6, Issue 9 (September 2017)
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story (view full-size image) In acute myeloid leukemia, it has been widely established that persistent residual leukemic burden, [...] Read more. In acute myeloid leukemia, it has been widely established that persistent residual leukemic burden, often referred to as measurable or minimal residual disease (MRD), after induction therapy or at the time of hematopoietic stem cell transplant is highly predictive for adverse clinical outcomes and can be used to identify patients likely to experience clinically evident relapse. In this review, we outline emerging modalities positioned to enhance MRD detection (including modern technologies enabling the digital quantification and tracking of individual DNA or RNA molecules, next-generation sequencing platforms, and high-resolution imaging capabilities) and discuss factors surrounding their integration into clinical practice. View Paper here